Verquvo will be listed for reimb at KRW 2,867 in KOR

Verquvo listed at KRW 2,867... Depakote Sprinkle Cap price 21.5%↑

MOHW seeks to amend Korea’s drug reimbursement list and according to the new drug listings and drug price adjustments on existing drugs

The 3 doses of Bayer Korea’s chronic heart failure treatment Verquvo Tab will be newly listed at KRW 2,867.

 

The price of Abbott Korea’s Depakote Sprinkle Cap (divalproex sodium) will be raised by nearly 22% upon the company’s request and negotiations.

 

According to industry sources on the 22nd, the Ministry of Health and Welfare is working on the ‘Amendment to the drug reimbursement list and reimbursement ceiling price table’ that contains the abovementioned changes that will become effective as of the 1st of the next month.

 

First, 5 new that contain 3 ingredients are waiting to be listed after successful negotiations with the NHIS.

 

The 2.5mg, 5mg, and 10mg formulations of Bayer Korea's Verquvo tablets will be listed at KRW 2,867.

 

Two new melphalan hydrochloride drugs, a treatment for multiple myeloma, will also be newly listed.

 

The price of Ace Pharma’s Megval Inj.

 

50mg and Korea HO Pharm’s Melpspal Inj.

 

50mg were set at KRW 110,000 per vial.

 

A total of three drugs have succeeded in negotiations and will receive raise in drug prices.

 

Among the drugs notified on the reimbursement list, these are drugs that successfully negotiated with the NHIS after requesting a price increase (application for adjustment) and passing deliberations by the Drug Reimbursement Evaluation Committee, and succeeded in negotiations with the NHIS.

 

In order for the price adjustment application to be accepted, all of the following conditions must be met: the drug must be▲ essential for patient care ▲ no alternative drug exists ▲ the cost of administration is lower than its alternatives, and is supplied by a single company.

 

In terms of the price increase by drug, Abbott Korea's Depakote Sprinkle Cap (divalproex sodium) will be supplied at a price of a 21.5% increase.

 

In addition, Korea Orphan & Essential Drug Center’s Xenazine Tab (tetrabenazine) will be priced at a 19.6% increase, and DID Bio’s Leclean Solution (sodium phosphate enema) will be set at a 28.7% increase in price and supplied.